Systemic Cancer Therapy Does Not Significantly Impact Early Vaccine-Elicited SARS-CoV-2 Immunity in Patients with Solid Tumors
Authors:
Open Access
Abstract
MRNA vaccines have been shown to be safe and effective in individuals with cancer. It is unclear, however, if systemic anti-cancer therapy impacts the coordinated cellular and humoral immune responses elicited by SARS-CoV-2 mRNA vaccines. To fill this knowledge gap, we assessed SARS-CoV-2 mRNA vaccine-elicited immunity in a cohort of patients with advanced solid tumors either under observation or receiving systemic anti-cancer therapy. This analysis revealed that SARS-CoV-2 mRNA vaccine-elicited cellular and humoral immunity was not significantly different in individuals with cancer receiving systemic anti-cancer therapy relative to individuals under observation. Furthermore, even though some patients exhibited suboptimal antibody titers after vaccination, SARS-CoV-2 specific cellular immune responses were still detected. These data suggest that antibody titers offer an incomplete picture of vaccine-elicited SARS-CoV-2 immunity in cancer patients undergoing active systemic anti-cancer therapy, and that vaccine-elicited cellular immunity exists even in the absence of significant quantities of SARS-CoV-2 specific antibodies.Keywords
Funding Information
- State University of New York
This publication has 24 references indexed in Scilit:
- Outcomes of COVID-19 in Patients With Cancer: Report From the National COVID Cohort Collaborative (N3C)Journal of Clinical Oncology, 2021
- Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer ConsortiumAnnals of Oncology, 2021
- Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemiaBlood, 2021
- A Systematic Review and Meta-Analysis of Cancer Patients Affected by a Novel CoronavirusJNCI Cancer Spectrum, 2021
- COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registryAnnals of Hematology, 2020
- Determinants of COVID-19 disease severity in patients with cancerNature Medicine, 2020
- Survival study of hospitalised patients with concurrent COVID‐19 and haematological malignanciesBritish Journal of Haematology, 2020
- COVID-19 and Cancer: a Comprehensive ReviewCurrent Oncology Reports, 2020
- Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse eventsJournal for ImmunoTherapy of Cancer, 2018
- Influenza Vaccination in Cancer Patients Undergoing Systemic TherapyClinical Medicine Insights: Oncology, 2014